Brian Park, PharmD

Drug Information Specialist https://www.dermatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Dermatology

FDA Rejects IV Tramadol NDA Again for Efficacy, Safety Concerns

Brian Park, PharmD

June 18, 2021

The Agency does not believe the data support the safety or efficacy of the treatment either as monotherapy or in combination with other analgesics.

Infections

Topical Antiviral Gel Looks Promising for Molluscum Contagiosum

Brian Park, PharmD

June 16, 2021

SB206 is an investigational nitric oxide-releasing topical gel that contains berdazimer sodium plus a hydrogel.

General Dermatology

Moderna Requests EUA for COVID-19 Vaccine Use in Adolescents

Brian Park, PharmD

June 16, 2021

The submission is based on data from the phase 2/3 TeenCOVE study, which included over 3700 US adolescents aged 12 to less than 18 years.

Psoriasis

Cosentyx Approved for Pediatric Plaque Psoriasis

Brian Park, PharmD

June 8, 2021

The approval was based on data from two phase 3 trials that evaluated the use of Cosentyx in patients 6 to 18 years of age with severe plaque psoriasis who were candidates for systemic therapy.

General Dermatology

FDA: Dietary Supplements Containing Kratom Seized

Brian Park, PharmD

June 7, 2021

The consumption of kratom can lead to serious medical outcomes.

Skin Injury

BD Surgiphor, a Ready-to-Use Iodine-Based Wound Irrigation System, Now Available

Brian Park, PharmD

June 3, 2021

BD Surgiphor is a pre-mixed, pre-labeled, single patient surgical wound irrigation system.

General Dermatology

CDC: COVID-19 Vaccine Breakthrough Infections Investigated

Brian Park, PharmD

June 3, 2021

The report included 10262 SARS-CoV-2 vaccine breakthrough infections in 46 US states and territories among 101 million fully vaccinated individuals as of April 30, 2021.

General Dermatology

Repigmentation Observed With Ruxolitinib Cream in Vitiligo Trials

Brian Park, PharmD

May 24, 2021

Results from both studies demonstrated that ruxolitinib met the primary endpoint with a greater proportion of patients achieving F-VASI75 at week 24.

General Dermatology

FDA: Consumer Electronics May Impact Implanted Medical Devices

Brian Park, PharmD

May 20, 2021

The FDA is advising patients with implanted medical devices to consider keeping consumer electronics at least 6 inches away from the implanted medical device.

General Dermatology

Zynrelef Approved to Treat Postoperative Pain for Up to 72 Hours

Brian Park, PharmD

May 19, 2021

The needle-free product is intended for single-dose administration only.

Next post in General Dermatology